查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126531

抗菌藥物敏感性測試：市場洞察、競爭格局和市場預測 - 2034 年

Antimicrobial Susceptibility Testing - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 全球抗菌藥物敏感性測試市場預計到 2025 年將達到 41.2815 億美元，到 2034 年將達到 64.7548 億美元。
  • 預計在 2026 年至 2034 年的預測期內，該市場將以 5.18% 的複合年成長率成長，其促進因素包括抗生素抗藥性威脅的加劇、感染疾病和敗血症負擔的加重以及合理使用抗生素計劃的擴展。
  • 以產品細分市場來看，預計到 2025 年，手動產品細分市場將引領抗菌藥物敏感性測試市場，佔 45% 的市場佔有率。
  • 按檢測方法分類，預計到 2025 年，紙錠擴散法將佔 34% 的市場佔有率，從而推動抗菌藥物敏感性測試市場的發展。
  • 按測試類型分類，預計到 2025 年，抗菌藥物測試細分市場將引領市場，佔抗菌藥物敏感性測試市場的 68%。
  • 按應用領域分類，預計到 2025 年，臨床診斷領域將佔抗菌藥物敏感性測試市場的 55%，從而推動市場成長。
  • 按最終用戶分類，醫院和診斷檢查室領域預計將成為市場的主要驅動力，到 2025 年將佔抗菌藥物敏感性測試市場的 60%。
  • 到 2025 年，北美將佔抗菌藥物敏感性測試市場 38% 的最大佔有率，但預計到 2034 年，亞太地區將實現最快的成長。

抗菌藥物敏感性試驗 (IPSS) 是指透過檢查室檢測來測量微生物對用於治療微生物的抗菌藥物的敏感性或抗藥性。這為臨床醫生選擇有效治療方案提供了指南，並支持監測和合理使用抗菌藥物，作為應對 IPSS 抗藥性的措施。該市場按產品供應、方法、檢測類型、應用和操作環境進行細分。按產品分類，可分為手動、自動和耗材，其中手動產品佔最大佔有率。按方法分類，包括紙錠擴散法、肉湯和瓊脂稀釋法、梯度擴散法、自動檢測以及用於測定最低抑菌濃度 (MIC) 的分子生物學方法。依檢測類型分類，可分為抗菌藥物檢測、抗真菌藥物檢測和抗寄生蟲藥物檢測。按應用分類，可分為臨床診斷、藥物發現和開發以及流行病學。按最終用戶分類，包括醫院和診斷檢查室、製藥和生物技術公司以及學術和研究機構。推動該市場發展的首要因素是全球日益嚴重的 IPSS 抗藥性威脅。因此，準確快速地確定藥物敏感性對於選擇有效的治療方案以及合理使用抗生素以維持其療效至關重要。此外，感染疾病和敗血症負擔的加重、合理用藥方案的推廣以及快速自動化檢測的普及（能夠快速提供檢測結果）也推動了市場成長。

抗菌藥物敏感性測試市場的主要市場促進因素

  • 世界衛生組織（世衛組織）已將日益嚴重的抗生素抗藥性列為全球最重要的健康威脅之一。每年約有130萬人死於細菌抗生素抗藥性，因此，藥敏試驗對於確定有效的治療策略至關重要。
  • 隨著感染疾病和敗血症的負擔日益加重，每年全球約有 1100 萬人死於敗血症，因此越來越需要快速、準確的藥敏試驗來指南治療。
  • 強制實施適當的抗生素使用方案和感染控制措施正在取得進展，這些措施依靠藥敏試驗來指導抗生素的合理使用，並防止抗藥性細菌的傳播。
  • 持續的技術進步包括直接從陽性血液培養檢體進行快速表現型敏感性測試、檢查室自動化以及分子生物學技術和質譜分析，這些技術能夠快速提供結果。
  • 醫院感染和多重抗藥性細菌感染的日益增多，導致藥敏試驗的數量和複雜性不斷增加。
  • 政府在抗生素抗藥性的診斷和監測方面採取了多項舉措，包括提供資金和監管支持，例如指定突破性醫療設備和強制執行抗生素管理。
  • 製藥和生物技術產業在發現和開發新型抗菌藥物的過程中，對藥敏試驗的需求日益成長。

推動抗菌藥物敏感性測試市場成長的因素

市場促進因素

抗生素抗藥性的威脅日益加劇

抗菌藥物敏感性檢測市場的主要驅動力是日益嚴重的全球抗菌藥物抗藥性威脅。這是因為應對抗藥性取決於識別哪些抗菌藥物對特定微生物仍然有效，而這正是敏感性檢測的關鍵功能。抗菌藥物抗藥性是指細菌、真菌和其他微生物進化出對治療藥物的抗藥性，世界衛生組織（WHO）已將其列為全球健康面臨的最大威脅之一。每年約有130萬人死於細菌抗菌藥物抗藥性，另有數百萬人死於其他相關疾病。臨床和公共衛生應對這一威脅依賴敏感性檢測，因為有效治療抗藥性感染疾病需要識別病原體仍然敏感的抗菌藥物，而旨在維持抗菌藥物有效性的合理使用和監測計劃也依賴這些檢測提供的敏感性數據。隨著抗藥性的增加和傳播，經驗性治療選擇變得不再可靠，因此對透過敏感性檢測提供的準確的、病原體特異性的敏感性資訊的需求日益成長。多重抗藥性細菌和廣譜抗藥性細菌的出現，使得藥敏試驗對於識別剩餘的少數有效藥物至關重要。抗菌藥物抗藥性是一個規模龐大且不斷擴大的全球性緊迫威脅，而藥敏試驗在臨床和公共衛生應對措施中發揮核心作用，從而為市場成長奠定了堅實的基礎。

感染疾病和敗血症負擔加重

感染疾病和敗血症負擔的日益加重是抗菌藥物敏感性檢測市場的主要驅動力。這是因為需要根據藥敏試驗結果進行治療的嚴重感染疾病病例數量決定了檢測需求，尤其是在敗血症方面，迫切需要快速檢測結果。血流感染疾病、呼吸道感染疾病、尿道感染和其他需要藥敏試驗指南治療的嚴重細菌感染疾病的負擔極為沉重，而且還在增加。這主要是由於人口老化、免疫力缺乏低下患者增加以及抗藥性流行率上升所致。敗血症是一種由感染疾病反應失調引起的危及生命的器官功能障礙，也造成了巨大的負擔，每年在全球造成約1100萬人死亡。快速且準確的藥敏試驗對於敗血症和其他嚴重感染疾病至關重要，因為在等待常規檢測結果期間長期進行經驗性頻譜治療會增加副作用風險、促進抗藥性產生並延緩治療方案的最佳化。縮短檢測週期所需的快速藥敏試驗需求尤其強勁。需要進行檢測的感染疾病負擔日益加重，加之人們越來越認知到快速標靶治療的價值，導致藥敏試驗的數量和緊迫性均上升。嚴重感染疾病和敗血症負擔沉重且持續增加，加上對藥敏試驗的依賴，是推動市場成長的主要因素。

市場限制因素

儘管抗生素抗藥性的威脅日益加劇，技術也日新月異，但抗生素敏感性檢測市場仍面臨許多重大限制因素。其中最主要的限制因素是傳統培養法耗時過長，而這類檢測方法仍佔絕大多數。這些方法依賴微生物的生長，需要一天以上的時間才能得出結果，從而延誤了治療方案的最佳化。雖然快速表現型和分子生物學檢測方法可以彌補這一不足，但其高昂的成本使其無法取代傳統方法。傳統方法仍然是標準方法，並佔了檢測的絕大部分。第二個限制因素是快速自動化系統的高成本。能夠加速和自動化敏感性檢測的先進設備需要大量的投資和營運成本，這限制了其應用，尤其是在新興市場的小規模檢查室和醫療機構。此外，耗材和檢測板的持續成本也增加了總擁有成本，儘管先進技術的臨床價值已得到公認，但仍阻礙了其廣泛應用。第三個限制因素是能夠進行敏感度檢測並解讀結果的熟練微生物學家和實驗室技術人員的短缺。藥敏試驗是一項需要專業訓練和技能的專門領域，合格人員的匱乏限制了檢測能力和質量，尤其是在新興市場。其他限制因素包括定義藥敏性和抗藥性的閾值複雜且不斷變化。這就要求檢查室在標準變更時更新其檢測方法和檢測組合。此外，檢測需氧、生長緩慢和難以培養的微生物的藥敏性也存在困難，同時也面臨報銷和檢查室預算方面的壓力，以及診斷設備相關的法律法規要求。這些因素——檢測時間、成本、人員和標準化——共同促成了藥敏試驗的穩定發展，儘管發展過程中也面臨許多實際限制。

目錄

第1章：抗菌藥物敏感性檢測市場：簡介

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章：抗菌藥物敏感性檢測市場：摘要整理

  • 主要亮點和市場概覽

第3章：抗菌藥物敏感性檢測市場：關鍵因素分析

  • 市場促進因素
    • 抗生素抗藥性的威脅日益加劇
    • 感染疾病和敗血症負擔加重
    • 抗菌藥物管理計劃的擴展
    • 快速檢測的技術進步
  • 市場限制因素
    • 使用傳統方法獲得檢測結果所需的時間很長。
    • 快速自動化系統成本高昂
    • 熟練人員短缺
  • 市場機遇
    • 快速表現型分析和自動化
    • 新興市場和不斷擴大的監控

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

第7章：抗菌藥物敏感性檢測市場：評估

  • 依產品
    • 手工製品
    • 自動化產品
    • 消耗品
  • 依方法類型
    • 紙錠擴散法
    • 稀釋法
    • 梯度擴散法
    • 自動化測試
    • 其他
  • 按測試類型
    • 抗菌
    • 抗真菌藥物
    • 抗寄生蟲藥物
  • 用途別
    • 臨床診斷
    • 藥物傳輸與開發
    • 流行病學
  • 最終用戶
    • 醫院/診斷檢查室
    • 製藥和生物技術公司
    • 學術研究機構
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：抗菌藥物敏感性檢測市場：競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章：抗菌藥物敏感性檢測市場：新創企業資金籌措與投資趨勢

第10章 抗菌藥物敏感性測試市場：公司概況與產品概況

  • bioMerieux SA
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation（Beckman Coulter）
  • Bruker Corporation
  • Merck KGaA
  • HiMedia Laboratories Pvt. Ltd.
  • Liofilchem Srl
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0917

Antimicrobial Susceptibility Testing Market Summary

Overview:

  • The global antimicrobial susceptibility testing market was valued at USD 4,128.15 million in 2025 and is projected to reach USD 6,475.48 million by 2034.
  • The market is expected to expand at a CAGR of 5.18% during the forecast period 2026-2034, supported by the escalating threat of antimicrobial resistance, the rising burden of infectious disease and sepsis, and the growth of antimicrobial stewardship programs.
  • By product, the manual products segment dominated the antimicrobial susceptibility testing market with a 45% share in 2025.
  • By method type, the disk diffusion segment dominated the antimicrobial susceptibility testing market with a 34% share in 2025.
  • By test type, the antibacterial testing segment dominated the antimicrobial susceptibility testing market with a 68% share in 2025.
  • By application, the clinical diagnostics segment dominated the antimicrobial susceptibility testing market with a 55% share in 2025.
  • By end-user, the hospitals and diagnostic laboratories segment dominated the antimicrobial susceptibility testing market with a 60% share in 2025.
  • North America accounted for the largest share of the antimicrobial susceptibility testing market at 38% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Antimicrobial susceptibility testing is the laboratory determination of the susceptibility or resistance of a microorganism to the antimicrobial agents used to treat it, guiding clinicians in the selection of effective therapy and supporting the surveillance and stewardship that combat antimicrobial resistance. The market is organized by the product supplied, the method employed, the type of test, the application, and the setting of use. By product, it divides into manual products, automated products, and consumables, with the manual products holding the largest share. By method, it spans disk diffusion, broth and agar dilution for the determination of the minimum inhibitory concentration, gradient diffusion, automated testing, and molecular methods. By test type it divides among antibacterial, antifungal, and antiparasitic testing, and by application among clinical diagnostics, drug discovery and development, and epidemiology. By end-user, it spans hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes. The market is driven above all by the escalating global threat of antimicrobial resistance, which makes the accurate and timely determination of susceptibility essential to the selection of effective therapy and to the stewardship that preserves the effectiveness of antimicrobials, and by the rising burden of infectious disease and sepsis, the growth of stewardship programs, and the migration toward the rapid and automated testing that accelerates the delivery of results.

Antimicrobial Susceptibility Testing Market Key Growth Drivers

  • The escalating global threat of antimicrobial resistance, identified by the World Health Organization as a top global health threat, with some 1.3 million deaths attributable to bacterial antimicrobial resistance each year, making susceptibility testing essential to guiding effective therapy.
  • The rising burden of infectious disease and sepsis, with some 11 million sepsis deaths worldwide each year, increases the demand for rapid and accurate susceptibility testing that guides treatment.
  • The growth of antimicrobial stewardship programs and infection control mandates, which depend upon susceptibility testing to guide appropriate antibiotic use and to combat the spread of resistant organisms.
  • Continuous technological advancement, including rapid phenotypic susceptibility testing directly from positive blood cultures, laboratory automation, and molecular and mass-spectrometry methods that accelerate the delivery of results.
  • The rising incidence of hospital-acquired infections and of multidrug-resistant organisms, which increases the volume and the complexity of susceptibility testing.
  • Government initiatives, funding, and regulatory support for the diagnosis and surveillance of antimicrobial resistance, including breakthrough device designations and stewardship mandates.
  • The growing demand of the pharmaceutical and biotechnology industries for susceptibility testing in the discovery and development of new antimicrobials.

Key Companies in Antimicrobial Susceptibility Testing Market

The competitive landscape is led by the following active manufacturers:

  • bioMerieux SA
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Beckman Coulter)
  • Bruker Corporation
  • Merck KGaA
  • HiMedia Laboratories Pvt. Ltd.
  • Liofilchem S.r.l.
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.

Factors Contributing to the Growth of the Antimicrobial Susceptibility Testing Market

Market Drivers

Escalating Threat of Antimicrobial Resistance

The foundational driver of the antimicrobial susceptibility testing market is the escalating global threat of antimicrobial resistance, because the response to resistance depends upon the determination of which antimicrobials remain effective against a given organism, which is the defining function of susceptibility testing. Antimicrobial resistance, in which bacteria, fungi, and other microorganisms evolve to withstand the drugs used to treat them, has been identified by the World Health Organization as one of the top threats to global health, and some 1.3 million deaths each year are attributable to bacterial antimicrobial resistance, with millions more associated with it. The clinical and public health response to this threat rests upon susceptibility testing, since the effective treatment of a resistant infection requires the identification of which antimicrobials the organism remains susceptible to, and the stewardship and surveillance programs that seek to preserve the effectiveness of antimicrobials depend upon the susceptibility data that testing provides. As resistance rises and spreads, the empirical selection of therapy becomes less reliable, and the need for the accurate, organism-specific susceptibility information that testing provides increases; the emergence of multidrug-resistant and extensively drug-resistant organisms makes susceptibility testing indispensable to identifying the few remaining effective agents. Because antimicrobial resistance is a large, rising, and urgent global threat, and because susceptibility testing is central to the clinical and public health response to it, this driver provides the most durable foundation for market growth.

Rising Burden of Infectious Disease and Sepsis

The rising burden of infectious disease and sepsis is a powerful driver of the antimicrobial susceptibility testing market, because the volume of serious infections that require susceptibility-guided therapy determines the demand for testing, and sepsis in particular creates urgent demand for rapid results. The burden of the bloodstream, respiratory, urinary, and other serious bacterial infections that require susceptibility testing to guide therapy is very large and rising, driven by aging, the growth of the immunocompromised population, and the rising prevalence of resistant organisms, and sepsis, the life-threatening organ dysfunction caused by a dysregulated response to infection, imposes an enormous burden, with some 11 million sepsis deaths worldwide each year. In sepsis and other serious infections, the rapid and accurate determination of susceptibility is critical, since prolonged empirical broad-spectrum therapy while awaiting conventional results increases the risk of adverse effects, promotes resistance, and delays the optimization of treatment, and the demand for rapid susceptibility testing that shortens this window is a particularly strong driver. The rising burden of the infections that require testing, and the recognition of the value of rapid, targeted therapy, together increase both the volume and the urgency of susceptibility testing. Because the burden of serious infection and sepsis is large, rising, and dependent upon susceptibility testing, this driver is a powerful contributor to market growth.

Market Restraints

Despite an escalating threat of antimicrobial resistance and rapid technological advances, the antimicrobial susceptibility testing market faces several material constraints. The most significant is the slow turnaround of the conventional culture-based methods that constitute the majority of testing, since these methods depend upon the growth of the organism and require a day or more to yield results, delaying the optimization of therapy, and although rapid phenotypic and molecular methods address this limitation, they carry higher costs and have not displaced the conventional methods, which remain the reference standard and the majority of testing. A second constraint is the high cost of the rapid and automated systems, since the advanced instruments that accelerate and automate susceptibility testing carry substantial acquisition and operating costs that restrict their adoption, particularly among smaller laboratories and providers in emerging markets, and the recurring cost of the consumables and panels adds to the total cost of ownership, so that the cost of the advanced methods constrains their diffusion even as their clinical value is recognized. A third constraint is the shortage of skilled microbiologists and laboratory technicians able to perform and interpret susceptibility testing, which is a specialized discipline requiring training and expertise, and the limited availability of qualified personnel constrains both the capacity and the quality of testing, particularly in emerging markets. Additional constraints include the complexity and continual evolution of the breakpoints that define susceptibility and resistance, which require laboratories to update their methods and panels as standards change; the difficulty of susceptibility testing for the fastidious, slow-growing, and difficult-to-culture organisms; the pressure of reimbursement and laboratory budgets; and the regulatory requirements governing diagnostic devices. Together, these turnaround, cost, workforce, and standardization factors ensure that growth, while steady, proceeds against genuine constraint.

Antimicrobial Susceptibility Testing Market Segment Analysis

The antimicrobial susceptibility testing market by product (manual products, automated products, and consumables), method type (disk diffusion, dilution, gradient diffusion, automated testing, and others), test type (antibacterial, antifungal, and antiparasitic testing), application (clinical diagnostics, drug discovery and development, and epidemiology), end-user (hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes), and geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product

Dominant Subsegment: Manual Products.

The manual products segment accounted for a 45% share of the antimicrobial susceptibility testing market in 2025. Manual products dominate the product structure because of the ease of availability and the lower cost of manual susceptibility testing relative to automated testing, and because the disk diffusion, gradient diffusion, and dilution methods that manual products enable remain the widely used and reference-standard methods of the microbiology laboratory. Manual products, including the antimicrobial disks, gradient diffusion strips, and dilution media and panels used to perform susceptibility testing by hand, are inexpensive, flexible, and broadly applicable, and they allow laboratories to test any organism against any panel of antimicrobials without the capital cost of automated instruments, sustaining their leading share, particularly in the cost-sensitive and lower-volume settings and in the emerging markets. The consumables consumed by both manual and automated testing, including the disks, strips, panels, and media, represent a large and recurring source of demand tied to test volume. The automated products segment, comprising the automated susceptibility testing instruments that improve throughput, consistency, and speed, constitutes the fastest-growing category, projected to grow at the highest rate as laboratories adopt automation to address rising volumes, the shortage of skilled personnel, and the demand for faster results, and the rapid phenotypic systems that report results directly from positive blood cultures are a particularly dynamic part of it. The manual products segment is expected to retain its leading share throughout the forecast period, while automated products grow fastest.

By Method Type

Dominant Subsegment: Disk Diffusion.

The disk diffusion segment accounted for a 34% share of the antimicrobial susceptibility testing market in 2025. Disk diffusion dominates the method structure owing to its flexibility, cost-effectiveness, and simplicity, which have made it the most widely used method of susceptibility testing in laboratories worldwide. In the disk diffusion method, antimicrobial-impregnated disks are placed on an agar plate inoculated with the organism, and the zone of inhibition of growth surrounding each disk is measured to determine susceptibility; the method is inexpensive, requires no specialized instruments, applies to a wide range of organisms and antimicrobials, and is standardized by international standard-setting bodies, sustaining its leading position. The low cost and flexibility of disk diffusion make it especially prevalent in cost-sensitive and lower-volume laboratories and in emerging markets, and its standardization and long clinical track record reinforce its use. Dilution methods, which determine the minimum inhibitory concentration through broth or agar dilution, constitute a substantial category valued for the quantitative result they provide, and gradient diffusion, which combines the simplicity of diffusion with a quantitative minimum inhibitory concentration result, constitutes a further important method. Automated testing, in which instruments perform and read the susceptibility test, constitutes the fastest-growing method, driven by the demand for throughput, consistency, and speed, and molecular and other methods complete the structure. Disk diffusion is expected to retain its leading share throughout the forecast period, while automated methods grow fastest.

Antimicrobial Susceptibility Testing Market Region Analysis

Dominant Region: North America

North America accounted for a 38% share of the global antimicrobial susceptibility testing market in 2025. The region is expected to account for the largest share of the global market, driven by the high prevalence and awareness of antimicrobial resistance, the strong adoption of advanced and rapid testing, well-developed reimbursement and healthcare infrastructure, federal initiatives promoting antimicrobial stewardship, and the presence and commercial strength of the leading diagnostics companies. The United States hosts a large and technologically advanced network of hospitals and clinical laboratories that perform a very high volume of susceptibility testing and are early adopters of the rapid phenotypic, automated, and molecular methods that define the modern field, and the strong reimbursement environment and high healthcare expenditure support the investment these systems require. The region leads in the response to antimicrobial resistance, with federal initiatives promoting antimicrobial stewardship strengthening demand, in the regulatory support for rapid diagnostics, including breakthrough device designations, and in the presence of the leading diagnostics manufacturers and strong research activity that support innovation. The high volume of testing in acute care settings ensures consistent utilization, and the regulatory support and clinical necessity keep the outlook robust. The region is expected to retain its leading position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the antimicrobial susceptibility testing market through 2034. The region is emerging as the principal growth engine of the market, propelled by very large populations, a high and rising burden of infectious disease and antimicrobial resistance, expanding healthcare access and laboratory infrastructure, rising healthcare expenditure, and increasing government initiatives against resistance across China, India, Japan, and Southeast Asia. The region combines the largest populations in the world with a high burden of bacterial infection and the antimicrobial resistance that susceptibility testing addresses, and the burden of resistance is particularly acute in parts of the region where antimicrobial use has been high and testing capacity limited. The expansion and modernization of diagnostic laboratory infrastructure, driven by rising incomes, expanding healthcare access, and growing public and private investment, is converting this burden into demand for testing, and governments are increasingly implementing national action plans, surveillance systems, and stewardship programs against resistance that require susceptibility testing. China combines a very large population with a rapidly developing diagnostics industry and is expected to register among the highest growth; India combines a very large population and infection burden with a rapidly expanding diagnostic laboratory sector, and Japan combines an advanced healthcare system with sophisticated testing. Regional growth is expected to exceed the global average across every segment.

Regional Commentary

North America

North America leads on value and adoption, holding a 38% share in 2025. The region combines a high burden and awareness of antimicrobial resistance, strong adoption of advanced and rapid testing, well-developed reimbursement and infrastructure, federal stewardship initiatives, and the commercial strength of the leading diagnostics companies. It leads in the response to resistance, in the regulatory support for rapid diagnostics, and in the high-volume testing of acute care. Near-term dynamics are shaped by the migration to rapid phenotypic and automated testing, the expansion of stewardship, the updating of breakpoints, and the response to multidrug-resistant organisms.

Europe

Europe is a large and sophisticated market, and the home region of several of the leading companies, including a major in vitro diagnostics leader, and it combines well-developed healthcare systems, strong stewardship and surveillance infrastructure, and the influential European breakpoint standards, with Germany, France, the United Kingdom, and Italy as principal markets. The region combines a substantial burden of infection and resistance with generally supportive public healthcare and a strong regulatory and public health emphasis upon antimicrobial resistance, and the European standard-setting body that establishes susceptibility breakpoints is highly influential. The In Vitro Diagnostic Medical Devices Regulation shapes the introduction of new tests, and the region sustains a competitive and advanced market served by both global and regional participants.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large populations, a high and rising burden of infection and antimicrobial resistance, expanding healthcare access and laboratory infrastructure, rising healthcare expenditure, and increasing government initiatives against resistance. The modernization of laboratory infrastructure is converting the large burden of resistance into demand for testing. China combines a very large population with a developing diagnostics industry and is expected to register among the highest growth; India combines a very large population and infection burden with a rapidly expanding laboratory sector, and Japan combines an advanced system with sophisticated testing. Both international and regional companies are expanding across the advanced and cost-effective segments. Growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. The burden of infection and antimicrobial resistance is high across all three, and the region carries a substantial and rising demand for susceptibility testing, with resistance a particular concern where antimicrobial use has been high and testing capacity limited. The Gulf states combine high healthcare investment with advanced laboratory infrastructure, and the larger Latin American markets, particularly Brazil, support established diagnostic laboratory sectors and growing adoption of advanced testing, together representing steady growth. Much of Africa carries a very high infection and resistance burden but faces severe constraints in laboratory infrastructure, personnel, and funding, so testing capacity is concentrated in the larger urban, private, and public health laboratories, with substantial unmet need. Regional growth will be driven by the high burden, expanding infrastructure, strengthening surveillance, and the availability of cost-appropriate testing.

Antimicrobial Susceptibility Testing Market Competitive Landscape

The global antimicrobial susceptibility testing market is classified as Moderately Concentrated. The market is led by a group of large diversified diagnostics and life-science companies with established susceptibility testing systems, consumables, and global reach, complemented by specialized microbiology and rapid-testing firms. Competition centers upon the breadth and standardization of the testing menu, the speed of results, the degree of automation, the installed base and its recurring consumable revenue, integration with identification and laboratory information systems, and increasingly upon rapid phenotypic testing and the response to antimicrobial resistance. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately concentrated, with a group of large diversified diagnostics and life-science companies holding significant combined share across the manual, automated, and consumable segments alongside specialized microbiology and rapid-testing firms, and with the installed base, menu breadth, standardization, and regulatory capability of the leaders constituting a barrier to entry.
  • Leading players: bioMerieux leads the field through its comprehensive identification and susceptibility portfolio, including automated and rapid phenotypic systems, with Becton Dickinson strong in automated susceptibility and molecular testing, Thermo Fisher and Danaher through Beckman Coulter strong in automated and manual systems, Bruker in mass-spectrometry-based methods, and Merck, HiMedia, Liofilchem, and Bio-Rad in consumables and manual products, alongside specialized rapid-testing firms including Accelerate Diagnostics, Q-linea, and Selux Diagnostics.
  • Geographic reach: The leading participants maintain global commercial, distribution, and service organizations, decisive because susceptibility testing is a global market requiring local sales, service, and regulatory presence, while specialized firms reach broader geographies through distribution, and regional manufacturers serve domestic and cost-sensitive markets, particularly across Asia-Pacific.
  • Product portfolio strength: Competitive advantage rests upon offering a broad and standardized testing menu spanning manual and automated methods, upon the speed of results, upon the automation that improves throughput and consistency, and upon the installed base that generates recurring consumable revenue, with the leaders competing on comprehensive and integrated identification and susceptibility solutions and specialized firms on a superior rapid phenotypic technology.
  • Pipeline strength: Development is concentrated in rapid phenotypic susceptibility testing directly from positive blood cultures, laboratory automation, molecular and genotypic resistance detection, expanded and updated antimicrobial panels, and the integration of susceptibility testing with identification and stewardship systems.
  • Strategic partnerships: Collaboration spans partnerships between diagnostics companies and hospitals, laboratories, and stewardship programs, the integration of susceptibility testing with identification, molecular, and laboratory information systems, and co-development and the acquisition of rapid-testing capability, exemplified by the acquisition of a rapid phenotypic testing company by a leading diagnostics firm.
  • M&A activity: Acquisition and consolidation have shaped the field, including the acquisition of rapid phenotypic and molecular testing capability by the diversified leaders, exemplified by the acquisition of a rapid antimicrobial susceptibility testing company and the integration of its technology into a comprehensive sepsis and susceptibility portfolio.
  • Innovation focus: Innovation is shifting toward rapid phenotypic testing that delivers susceptibility results directly from positive blood cultures in hours, laboratory automation that addresses throughput and personnel constraints, molecular and genotypic resistance detection, artificial intelligence in interpretation, and the integration of susceptibility testing with identification and stewardship.
  • Regulatory standing: Regulatory clearance and approval for diagnostic devices in the major jurisdictions, including United States Food and Drug Administration clearance and CE marking, together with the breakthrough device designations that expedite the review of high-value rapid systems, are decisive credentials, and the standardization of susceptibility testing by the international breakpoint-setting bodies both governs the market and rewards the standardization and regulatory capability of the leading companies.

Antimicrobial Susceptibility Testing Market Recent Developmental Activities

In June 2024, bioMerieux received United States Food and Drug Administration 510(k) clearance for its VITEK REVEAL antimicrobial susceptibility testing system, which reports phenotypic susceptibility results for Gram-negative bacteria directly from positive blood cultures in an average of some five and a half hours, enabling same-day treatment decisions in bacteremic sepsis. Strategic significance: the clearance of a rapid phenotypic system reporting directly from positive blood cultures addressed the central limitation of conventional susceptibility testing, its slow turnaround, in the urgent setting of sepsis, and reinforced the migration of the market toward rapid, actionable results that support antimicrobial stewardship.

Antimicrobial Susceptibility Testing Market Segmentation

Antimicrobial Susceptibility Testing Market Assessment by Product

  • Manual Products
  • Automated Products
  • Consumables

Antimicrobial Susceptibility Testing Market Assessment by Method Type

  • Disk Diffusion
  • Dilution
  • Gradient Diffusion
  • Automated Testing
  • Others

Antimicrobial Susceptibility Testing Market Assessment by Test Type

  • Antibacterial
  • Antifungal
  • Antiparasitic

Antimicrobial Susceptibility Testing Market Assessment by Application

  • Clinical Diagnostics
  • Drug Discovery and Development
  • Epidemiology

Antimicrobial Susceptibility Testing Market Assessment by End-User

  • Hospitals and Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Antimicrobial Susceptibility Testing Market Assessment by Geography

  • North America
  • United States Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Canada Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Mexico Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Europe
  • France Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Germany Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • United Kingdom Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Italy Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Spain Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Rest of Europe Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Japan Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • India Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Australia Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • South Korea Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Africa Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • South America Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)

Key Takeaways from the Antimicrobial Susceptibility Testing Market Report Study

  • Market size analysis for the current Antimicrobial Susceptibility Testing market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.
  • Key companies dominating the global Antimicrobial Susceptibility Testing market.
  • Various opportunities available for competitors in the Antimicrobial Susceptibility Testing market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current Antimicrobial Susceptibility Testing market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for Antimicrobial Susceptibility Testing market growth in the future?

Target audience who can benefit from this Antimicrobial Susceptibility Testing market report study

  • Antimicrobial Susceptibility Testing product providers
  • Research organizations and consulting companies
  • Antimicrobial Susceptibility Testing -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Antimicrobial Susceptibility Testing
  • Various end-users who want to know more about the Antimicrobial Susceptibility Testing market and the latest technological developments in the Antimicrobial Susceptibility Testing market.

Frequently Asked Questions:

Q1. At what rate is the antimicrobial susceptibility testing market expected to grow?

The global antimicrobial susceptibility testing market is projected to grow at a compound annual growth rate of 5.18% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the antimicrobial susceptibility testing market?

The global antimicrobial susceptibility testing market was valued at USD 4,128.15 million in 2025 and is projected to reach USD 6,475.48 million by 2034.

Q3. Which region dominates the antimicrobial susceptibility testing market?

North America dominated the antimicrobial susceptibility testing market with a 38% share in 2025 on a modeled basis, driven by the high burden and awareness of antimicrobial resistance, strong adoption of advanced and rapid testing, well-developed reimbursement and infrastructure, federal initiatives promoting antimicrobial stewardship, and the presence of the leading diagnostics companies. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by very large populations, a high and rising burden of infection and resistance, expanding healthcare access and laboratory infrastructure, and increasing government initiatives across China, India, Japan, and Southeast Asia.

Table of Contents

1. Antimicrobial Susceptibility Testing Market Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Antimicrobial Susceptibility Testing Market Executive Summary

  • 2.1. Key Highlights and Market Snapshot

3. Antimicrobial Susceptibility Testing Market Key Factors Analysis

  • 3.1. Market Drivers
    • 3.1.1. Escalating Threat of Antimicrobial Resistance
    • 3.1.2. Rising Burden of Infectious Disease and Sepsis
    • 3.1.3. Growth of Antimicrobial Stewardship Programs
    • 3.1.4. Technological Advancement Toward Rapid Testing
  • 3.2. Market Restraints
    • 3.2.1. Slow Turnaround of Conventional Methods
    • 3.2.2. High Cost of Rapid and Automated Systems
    • 3.2.3. Shortage of Skilled Personnel
  • 3.3. Market Opportunities
    • 3.3.1. Rapid Phenotypic Testing and Automation
    • 3.3.2. Emerging Markets and Surveillance Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Antimicrobial Susceptibility Testing Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Antimicrobial Susceptibility Testing Market Assessment

  • 7.1. By Product
    • 7.1.1. Manual Products
    • 7.1.2. Automated Products
    • 7.1.3. Consumables
  • 7.2. By Method Type
    • 7.2.1. Disk Diffusion
    • 7.2.2. Dilution
    • 7.2.3. Gradient Diffusion
    • 7.2.4. Automated Testing
    • 7.2.5. Others
  • 7.3. By Test Type
    • 7.3.1. Antibacterial
    • 7.3.2. Antifungal
    • 7.3.3. Antiparasitic
  • 7.4. By Application
    • 7.4.1. Clinical Diagnostics
    • 7.4.2. Drug Discovery and Development
    • 7.4.3. Epidemiology
  • 7.5. By End-User
    • 7.5.1. Hospitals and Diagnostic Laboratories
    • 7.5.2. Pharmaceutical and Biotechnology Companies
    • 7.5.3. Academic and Research Institutes
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.1.2. Canada Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.1.3. Mexico Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2. Europe
      • 7.6.2.1. France Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.2.2. Germany Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.2.3. United Kingdom Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.2.4. Italy Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.2.5. Spain Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.2.6. Rest of Europe Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.3.2. Japan Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.3.3. India Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.3.4. Australia Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.3.5. South Korea Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.3.6. Rest of Asia-Pacific Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.4. Rest of the World
      • 7.6.4.1. Middle East Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.4.2. Africa Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
      • 7.6.4.3. South America Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)

8. Antimicrobial Susceptibility Testing Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Antimicrobial Susceptibility Testing Market Startup Funding and Investment Trends

10. Antimicrobial Susceptibility Testing Market Company and Product Profiles

  • 10.1. bioMerieux SA
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Listing
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Becton, Dickinson and Company
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Listing
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Thermo Fisher Scientific Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Listing
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. Danaher Corporation (Beckman Coulter)
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Listing
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. Bruker Corporation
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Listing
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. Merck KGaA
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Listing
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. HiMedia Laboratories Pvt. Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Listing
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. Liofilchem S.r.l.
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Listing
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. Accelerate Diagnostics, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Listing
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Bio-Rad Laboratories, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Listing
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Table 2: Global Antimicrobial Susceptibility Testing Market Size by Product in USD million (2023-2034)
  • Table 3: Global Antimicrobial Susceptibility Testing Market Size by Method Type in USD million (2023-2034)
  • Table 4: Global Antimicrobial Susceptibility Testing Market Size by Test Type in USD million (2023-2034)
  • Table 5: Global Antimicrobial Susceptibility Testing Market Size by Application in USD million (2023-2034)
  • Table 6: Global Antimicrobial Susceptibility Testing Market Size by End-User in USD million (2023-2034)
  • Table 7: Antimicrobial Susceptibility Testing Market Size in North America in USD million (2023-2034)
  • Table 8: Antimicrobial Susceptibility Testing Market Size in the United States in USD million (2023-2034)
  • Table 9: Antimicrobial Susceptibility Testing Market Size in Canada in USD million (2023-2034)
  • Table 10: Antimicrobial Susceptibility Testing Market Size in Mexico in USD million (2023-2034)
  • Table 11: Antimicrobial Susceptibility Testing Market Size in Europe in USD million (2023-2034)
  • Table 12: Antimicrobial Susceptibility Testing Market Size in France in USD million (2023-2034)
  • Table 13: Antimicrobial Susceptibility Testing Market Size in Germany in USD million (2023-2034)
  • Table 14: Antimicrobial Susceptibility Testing Market Size in the United Kingdom in USD million (2023-2034)
  • Table 15: Antimicrobial Susceptibility Testing Market Size in Italy in USD million (2023-2034)
  • Table 16: Antimicrobial Susceptibility Testing Market Size in Spain in USD million (2023-2034)
  • Table 17: Antimicrobial Susceptibility Testing Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 18: Antimicrobial Susceptibility Testing Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 19: Antimicrobial Susceptibility Testing Market Size in China in USD million (2023-2034)
  • Table 20: Antimicrobial Susceptibility Testing Market Size in Japan in USD million (2023-2034)
  • Table 21: Antimicrobial Susceptibility Testing Market Size in India in USD million (2023-2034)
  • Table 22: Antimicrobial Susceptibility Testing Market Size in Australia in USD million (2023-2034)
  • Table 23: Antimicrobial Susceptibility Testing Market Size in South Korea in USD million (2023-2034)
  • Table 24: Antimicrobial Susceptibility Testing Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 25: Antimicrobial Susceptibility Testing Market Size in the Rest of the World in USD million (2023-2034)
  • Table 26: Antimicrobial Susceptibility Testing Market Size in the Middle East in USD million (2023-2034)
  • Table 27: Antimicrobial Susceptibility Testing Market Size in Africa in USD million (2023-2034)
  • Table 28: Antimicrobial Susceptibility Testing Market Size in South America in USD million (2023-2034)
  • Table 29: Antimicrobial Susceptibility Testing Market Competitive Landscape
  • Table 30: Antimicrobial Susceptibility Testing Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Antimicrobial Susceptibility Testing Market Drivers
  • Figure 2: Antimicrobial Susceptibility Testing Market Restraints
  • Figure 3: Antimicrobial Susceptibility Testing Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Antimicrobial Susceptibility Testing Market (the United States)
  • Figure 6: Regulatory Analysis of the Antimicrobial Susceptibility Testing Market (Europe)
  • Figure 7: Regulatory Analysis of the Antimicrobial Susceptibility Testing Market (Japan)
  • Figure 8: Regulatory Analysis of the Antimicrobial Susceptibility Testing Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Antimicrobial Susceptibility Testing Market
  • Figure 10: Competitive Analysis of the Antimicrobial Susceptibility Testing Market
  • Figure 11: Global Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • Figure 12: Global Antimicrobial Susceptibility Testing Market Size by Product in USD million (2023-2034)
  • Figure 13: Global Antimicrobial Susceptibility Testing Market Size by Method Type in USD million (2023-2034)
  • Figure 14: Global Antimicrobial Susceptibility Testing Market Size by Test Type in USD million (2023-2034)
  • Figure 15: Global Antimicrobial Susceptibility Testing Market Size by Application in USD million (2023-2034)
  • Figure 16: Global Antimicrobial Susceptibility Testing Market Size by End-User in USD million (2023-2034)
  • Figure 17: Antimicrobial Susceptibility Testing Market Size in North America in USD million (2023-2034)
  • Figure 18: Antimicrobial Susceptibility Testing Market Size in the United States in USD million (2023-2034)
  • Figure 19: Antimicrobial Susceptibility Testing Market Size in Canada in USD million (2023-2034)
  • Figure 20: Antimicrobial Susceptibility Testing Market Size in Mexico in USD million (2023-2034)
  • Figure 21: Antimicrobial Susceptibility Testing Market Size in Europe in USD million (2023-2034)
  • Figure 22: Antimicrobial Susceptibility Testing Market Size in France in USD million (2023-2034)
  • Figure 23: Antimicrobial Susceptibility Testing Market Size in Germany in USD million (2023-2034)
  • Figure 24: Antimicrobial Susceptibility Testing Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 25: Antimicrobial Susceptibility Testing Market Size in Italy in USD million (2023-2034)
  • Figure 26: Antimicrobial Susceptibility Testing Market Size in Spain in USD million (2023-2034)
  • Figure 27: Antimicrobial Susceptibility Testing Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 28: Antimicrobial Susceptibility Testing Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 29: Antimicrobial Susceptibility Testing Market Size in China in USD million (2023-2034)
  • Figure 30: Antimicrobial Susceptibility Testing Market Size in Japan in USD million (2023-2034)
  • Figure 31: Antimicrobial Susceptibility Testing Market Size in India in USD million (2023-2034)
  • Figure 32: Antimicrobial Susceptibility Testing Market Size in Australia in USD million (2023-2034)
  • Figure 33: Antimicrobial Susceptibility Testing Market Size in South Korea in USD million (2023-2034)
  • Figure 34: Antimicrobial Susceptibility Testing Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 35: Antimicrobial Susceptibility Testing Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 36: Antimicrobial Susceptibility Testing Market Size in the Middle East in USD million (2023-2034)
  • Figure 37: Antimicrobial Susceptibility Testing Market Size in Africa in USD million (2023-2034)
  • Figure 38: Antimicrobial Susceptibility Testing Market Size in South America in USD million (2023-2034)
  • Figure 39: Antimicrobial Susceptibility Testing Market Competitive Landscape
  • Figure 40: Antimicrobial Susceptibility Testing Market Startup Funding and Investment Trends